Twist Bioscience Expands Express Genes Rapid Synthesis Service
- None.
- None.
Insights
The announcement by Twist Bioscience signifies a strategic move to enhance their service offerings in the gene synthesis market. The expansion of Twist Express Genes to include larger DNA preparations up to 1 milligram addresses a critical need for rapid synthesis services, which is particularly relevant for sectors engaged in high-throughput research and development activities. This capability to provide larger quantities of synthetic DNA with a swift turnaround can be a competitive advantage for Twist Bioscience, potentially increasing its market share.
From a market perspective, the responsive pricing model that reflects market demand and manufacturing capacity is indicative of the company's agility and customer-centric approach. The ability to scale and meet diverse customer requirements, from small to large DNA prep sizes, could lead to an increase in customer acquisition and retention. However, this might also put pressure on operational capabilities and supply chain management, necessitating careful monitoring of quality control as service volume increases.
The biotechnology sector is heavily reliant on the timely availability of high-quality synthetic DNA for various applications, including drug discovery, genetic research and industrial biotech processes. Twist Bioscience's announcement of the expanded gene synthesis service is a significant development for researchers requiring larger quantities of DNA. The NGS-verified clonally perfect genes ensure high fidelity, which is paramount for precision in experiments and downstream applications.
For pharmaceutical and biotechnology companies, the shortened lead times for gene synthesis can accelerate the R&D pipeline, potentially reducing the time to market for new therapies and products. This enhancement in service could support more rapid iterations of the design-build-test-learn cycle, central to synthetic biology and genetic engineering projects. The environmental aspect of a reduced carbon footprint in gene manufacturing, as mentioned in Twist's ESG report, may also appeal to stakeholders increasingly concerned with sustainability issues.
Twist Bioscience's mention of a minimal carbon footprint in the production of a single gene, as reported in their ESG documentation, is an important consideration for environmentally conscious stakeholders. As companies and investors become more attuned to the environmental impact of their operations and supply chain, Twist's commitment to sustainability could enhance its reputation and appeal to a segment of the market that prioritizes eco-friendly practices.
It is essential to scrutinize the veracity of these claims and the methodology used to quantify the carbon footprint. As the demand for Twist's services potentially grows due to the expanded offerings, the overall environmental impact may increase even if the per-gene carbon footprint is minimal. Continuous improvements in efficiency and environmental performance will be key to maintaining a positive perception among stakeholders who value sustainability alongside innovation.
The Express Genes offering, initially launched in November 2023, now extends to larger midiprep (10μg to 100 μg) and maxiprep (100μg to 1mg) DNA preparations. As with Twist standard speed Clonal Genes, all Twist Express Genes are NGS-verified as clonally perfect.
“Since the initial launch of our Express Genes service in November, we have received positive and enthusiastic feedback from existing customers on our consistent and rapid turnaround time. By expanding Express Genes to include midiprep and maxiprep, we can now offer rapid gene synthesis at all gene prep scales, enabling large scale experimentation for pharmaceutical, biotechnology, academic and industrial chemical researchers,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “With the expanded offering of Twist Express Genes, more researchers can gain access to Twist genes fast and at scale, including those using alternative providers and those cloning their own genes. The ability to order and receive synthetic DNA fast and at scale means more time for cutting-edge research, more make-test-learn cycles, and an accelerated journey to game-changing discoveries.”
Twist leverages its ability to miniaturize the chemical reaction to create DNA using its silicon-based DNA synthesis platform along with expertise, software, optimized processes and the expanded layout of its Wilsonville facility to deliver Clonal Genes and Gene Fragments at scale and with rapid turnaround times. Twist’s Express Genes are offered with dynamic pricing, which reflects market demand and manufacturing capacity in a responsive premium price. Customers are able to quickly and easily place orders for Express Genes through Twist’s ecommerce platform.
Twist Express Genes
Twist Express Genes are 0.3kb to 5.0kb in length. Due to scale enabled by Twist’s platform, orders of any size both small and large can be filled, and as with standard speed Twist Clonal Genes, Twist Express Genes are NGS sequence-verified as one hundred percent accurate. Twist Express Genes can be cloned into catalog vectors or custom vectors so that customers can move right to experimentation. They can also be shipped in customers’ preferred delivery formats, including tubes and plates. For more information and product specifications click here.
Current turnaround times for some Twist Bioscience products:
- Express Genes1 (50ng-10µg): starting at 5 business days, now for up to 10µg
- Standard Clonal Genes (50ng-10µg): starting at 10 business days
- Express Genes1 (10µg-1mg): starting at 8 business days
- Standard Clonal Genes (10µg-1mg): starting at 13 business days
Twist quantified the minimal carbon footprint of manufacturing a single gene in its 2023 ESG report. View the report here: https://www.twistbioscience.com/company/esg?tab=environmental
1 Express Clonal Genes ship in 5-7 business days. DNA prep sizes including 10 μg - 100 μg, and 100 μg - 1 mg may incur an additional 3-5 days for synthesis. Orders placed outside of the US will incur additional delivery turnaround time. Express Genes orders that require new custom vector onboarding will incur an additional 1-2 weeks for processing.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube | Instagram
Twist Bioscience Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the turnaround time of the Twist Express Gene offering for midiprep and maxiprep DNA preparations, and Twist Bioscience’s ability to service pharmaceutical, biotechnology, academic and industrial chemical researchers using genes for large scale experimentation. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the ability to achieve the expected benefits of Twist Bioscience’s restructuring activities and reduced investments in DNA data storage; the ability to attract new customers and retain and grow sales from existing customers; the ability of Twist Bioscience to achieve sufficient revenue to achieve or maintain positive cash flow from operations or profitability in any given period; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist Bioscience is developing obsolete or non-competitive; uncertainties of the retention of significant customers; the ability of Twist Bioscience to successfully integrate acquired companies and to achieve expected benefits from acquisitions; supply chain and other disruptions; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience’s patents or proprietary rights; and the risk that Twist Bioscience’s proprietary rights may be insufficient to protect its technologies. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience’s business in general, see Twist Bioscience’s risk factors set forth in Twist Bioscience’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on November 21, 2023 and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240124209204/en/
For Investors:
Angela Bitting
SVP, Corporate Affairs
925-202-6211
abitting@twistbioscience.com
For Media:
Amanda Houlihan
Communications Manager
774-265-5334
ahoulihan@twistbioscience.com
Source: Twist Bioscience Corporation
FAQ
What is the ticker symbol for Twist Bioscience Corporation?
What is the turnaround time for Twist Express Genes service?
What is the expanded offering of Twist Express Genes?
What is the carbon footprint of manufacturing a single gene by Twist Bioscience?
What are the benefits of the expanded offering of Twist Express Genes?
How can customers place orders for Twist Express Genes?
